Hyponatremia by oxcarbacepin in multiple sclerosis, a case to take account
PDF (Español (España))


multiple sclerosis

How to Cite

Beltrán D, Montoya M. Hyponatremia by oxcarbacepin in multiple sclerosis, a case to take account. Rev. Colomb. Nefrol. [Internet]. 2017 Jul. 27 [cited 2022 May 18];4(2):226-32. Available from: https://revistanefrologia.org/index.php/rcn/article/view/248


Hyponatremia is one of the adverse effects in patients treated with oxcarbazepine. This can be seen masked by multiple symptoms which are simply attributable to other diseases, but we must always keep it in mind in a patient with a history of taking that medication. Many of patients are asymptomatic; Doses lower than 120 mmol/L show symptoms of severity which presented a patient with multiple sclerosis, which we will show below, so that diagnostic ability of clinicians plays a fundamental role. This is why the case is exposed in which a woman treated with oxcarbazepine for one of the clinical forms of multiple sclerosis, arrives at emergency departament with manifestations of this electrolytic disorder. For this reason, the clinical case served by the authors is chosen directly.
It is concluded that this adverse reaction is not uncommon and that it must be taken into account in the differential diagnosis.
PDF (Español (España))


1. Dong X, Leppik IE, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology. 2005;65(12):1976-78. Disponible en: http://doi.org/10.1212/01.wnl.0000188819.45330.90

2. Glauser TA. Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy 2001;21:904-19. Disponible en: https://doi.org10.1592/phco.21.11.904.34513

3. Sachdeo R, Wasserstein A, Mesenbrink J, D’Souza J. Effects of oxcarbazepine on sodium concentration and water handling. Ann Neurol. 2002; 51(5): 613-20. Disponible en: https://doi.org/10.1002/ana.10190

4. Food and Drug Administration. Highlights of Prescribing Information [Internet]. East Hanover: Novartis Pharmaceuticals Corporation. 2011. 34 p. Disponible en: http://www.accessdata.fda.gov/drugsatfda_docslabel/2014/021014s035,021285s030lbl.pdf

5. Schmidt D, Arroyo S, Baulac M, et al. Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view. Acta Neurol Scand. 2001;104(3):167-70. Disponible en: https://doi.org 10.1034/j.1600-0404.2001.00870.x

6. Berghuis B, de Haan G-J., van den Broek, MPH., Sander JW, Lindhout D, Koeleman, BPC. Epidemiology, pathophysiology and putative genetic basis of carbamazepine- and oxcarbazepine-induced hyponatremia. Eur J Neurol. 2016,23(9):139-9. Disponible en: https://www.doi.org/10.1111/ene.13069

7. Spasovski G, Vanholder, Allolio B, et al. Clinical practice guide on the diagnosis and treatment of hyponatremia. Eur J Endocrinol. 2014;170: L5-6. Disponible en https//:doi.org/doi: 10.1530/EJE-14-0393

8. Koch MW, Polman SK. Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev. 2009;4:Art. No. CD006453. Disponible en: https://doi.org/10.100214651858.CD006453.pub2
No national or foreign publication may partially or totally reproduce or translate Revista Colombiana de Nefrología articles or abstracts without prior written permission from the journal’s Editorial Board.


Download data is not yet available.